This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month

3 hours ago 3

Jonathan Ponciano, The Motley Fool

Sun, March 22, 2026 astatine 12:00 PM CDT 3 min read

On February 17, 2026, One Fin Capital Management afloat exited its presumption successful GRAIL (NASDAQ:GRAL), selling astir 380,000 shares worthy $22.47 million.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, One Fin Capital Management reported the implicit merchantability of its 380,000-share involvement successful GRAIL. The money reported a quarter-end presumption worth alteration of $22.47 cardinal arsenic a effect of the sale.

The liquidation means GRAIL present represents 0% of the fund’s 13F AUM, down from 7.4% successful the anterior period.
Top holdings aft the filing:
- NYSE:COF: $31.88 cardinal (12.1% of AUM)
- NASDAQ:NXT: $26.13 cardinal (9.9% of AUM)
- NYSE:RKT: $25.75 cardinal (9.8% of AUM)
- NASDAQ:DRVN: $24.30 cardinal (9.2% of AUM)
- NYSE:NSC: $23.10 cardinal (8.8% of AUM)
As of Friday, shares of GRAIL were priced astatine $46.84, up 68% this past year, good outperforming the S&P 500, which is alternatively up astir 15% successful the aforesaid period.

Metric

Value

Market Capitalization	$1.9 billion
Price (as of Friday)	$46.84
Revenue (TTM)	$147.2 million
Net Income (TTM)	($408.35 million)

GRAIL develops aboriginal crab detection technologies, including the Galleri screening trial and diagnostic immunodeficiency for cancer, with further enactment connected minimal residual illness and post-diagnostic tools.
The steadfast generates gross chiefly done income of proprietary diagnostic tests and related services, targeting the healthcare diagnostics market.
Its main customers see healthcare providers, clinicians, and asymptomatic individuals implicit 50 seeking proactive crab screening solutions.

GRAIL is simply a biotechnology institution specializing successful blood-based multi-cancer aboriginal detection and diagnostic solutions. Leveraging precocious genomics and information science, it aims to alteration crab screening and diagnosis astatine scale. Its proprietary exertion and absorption connected aboriginal detection presumption it arsenic a person successful the rapidly evolving aesculapian diagnostics landscape.

This determination matters due to the fact that it shows subject close earlier a high-conviction maturation communicative dealt with a stunning blow. GRAIL had been, and successful immoderate ways inactive is, a standout performer, riding optimism astir its aboriginal crab detection level and beardown commercialized traction, including much than 185,000 Galleri tests sold and gross maturation into the $147 cardinal scope past year. But underneath that momentum, the concern inactive carries dense losses and execution hazard tied to regulatory support and adoption curves.

That hostility came into absorption fast. A sharp, astir 50% single-day driblet pursuing net highlights conscionable however fragile sentiment tin beryllium erstwhile expectations tally up of fundamentals.

One Fin’s broader portfolio, meanwhile, leans toward a premix of financials, industrials, and consumer-facing names, suggesting a absorption connected companies with much predictable currency flows and clearer near-term net visibility. Ultimately, for semipermanent investors, this seems similar a bully reminder that subject matters, and balancing hazard aft staggering upside tin assistance you beryllium retired immoderate steep declines.

Read Entire Article